Intracranial microinfusion of pancreastatin elevates blood glucose, free fatty acids, and corticosterone in rats

Effect of chromogranin A on central autonomic control of blood pressure

We investigated the effect of exogenous chromogranin A (CgA) on central autonomic structures involved in the control of blood pressure. Actions of CgA were assessed on neurons in the rostral ventrolateral medulla, the most important brain area for cardiovascular control and for generation of sympathetic activity. Changes in renal sympathetic nerve activity, arterial pressure, heart rate, and somato-sympathetic reflexes were measured after microinjections of chromogranin A into the rostral ventrolateral medulla of anesthetized rats. The sites of microinjection of chromogranin A were determined from well known sympathetic and cardiovascular responses to microinjection of the inhibitory amino acid glycine. Significant decreases in renal nerve activity and arterial blood pressure began 10 min after microinjection of chromogranin A into the rostral ventrolateral medulla, and the maximum effect was observed at 20 min. Moreover, the bulbar component of somato-sympathetic reflexes was depressed 20 min after microinjections of chromogranin A. Our results indicate that chromogranin A can modify the activity of neurons within rostral ventrolateral medulla involved in regulation of cardiovascular autonomic control.

Secretion of pancreastatins from isolated, perfused, porcine adrenal glands

Pancreastatin is a 49 amino acid peptide with a C-terminal glycine amide originally isolated from porcine pancreas. There are strong indications that pancreastatin is derived from chromogranin A, since the amino acid sequence 240-288 in porcine chromogranin A contains pancreastatin flanked by typical signals for proteolytic processing. Several molecular forms of immunoreactive pancreastatin have been reported to be present in porcine adrenal medulla, but no information on the secretion of the peptides is available. We studied stimuli for the release of immunoreactive pancreastatin from adrenal glands as well as the molecular nature of the released immunoreactivity using isolated, perfused, porcine adrenal glands with intact splanchnic nerve supply and a radioimmunoassay specific for the C-terminal glycine amide of porcine pancreastatin in combination with chromatography. Stimulation of the splanchnic nerves greatly enhanced the release of immunoreactive pancreastatin by a mechanism that seems to involve cholinergic nicotinic transmission. The pancreastatin immunoreactivity was due to large amounts of a N-terminally extended pancreastatin form, possibly corresponding to the chromogranin A(1-288) fragment and small amounts of pancreastatin and a C-terminal pancreastatin fragment. Adrenal extracts also contained unprocessed chromogranin A. We conclude that in the porcine adrenals at least 25% of chromogranin A is processed to smaller molecular forms with the pancreastatin sequence forming their C-terminus. These forms appear to be released in parallel with the catecholamines.

Pancreastatin decreases plasma epinephrine levels in surgical stress in the rat

Pancreastatin is a novel peptide, isolated from porcine pancreatic extracts, that is known to be derived from chromogranin A. Since chromogranin A-derived peptides have been shown to control secretion from chromaffin cells, we studied the effect of rat pancreastatin, injected intravenously via portal vein, on plasma catecholamine levels in the anesthetized, laparotomized rat. Rat pancreastatin reversibly decreased plasma epinephrine levels, in a dose-dependent manner, without modifying plasma norepinephrine and dopamine levels. These findings suggest that pancreastatin, released from the gastroenteropancreatic system or derived from chromogranin A, may have a role controlling secretion from the adrenal medulla in surgical stress.

Chromogranin A, a soluble synaptic vesicle protein, is found in cortical neurons other than previously defined peptidergic neurons in the human neocortex

Neuropeptides in the cerebral cortex have previously been identified in non-pyramidal neurons only. By comparing the location of chromogranin A (CgA), a soluble protein of large dense-core synaptic vesicles, with that of SMI-32, neuropeptide Y (NPY), parvalbumin (PV) and calbindin (CaBP) using double label immunohistochemistry, we demonstrate that CgA is present in pyramidal neurons as well as in several subtypes of non-pyramidal neurons.

Role of hypothalamic paraventricular nucleus alpha- and beta-adrenergic receptors in regulation of blood glucose, free fatty acids and corticosterone

The potential roles of adrenergic and noradrenergic terminals in the hypothalamic paraventricular nucleus in the regulation of blood glucose and free fatty acids, the two major metabolic fuels, were examined. Corticosterone was also measured, both to assess the specificity of any effects for metabolic fuels, and because endogenous catecholamines in this site have previously been implicated in corticosterone regulation. In the first experiment adult male albino rats having chronically implanted guide cannulae aimed at the hypothalamic paraventricular nucleus or the caudate nucleus received microinjections of the agonists methoxamine (alpha 1), clonidine (alpha 2), and isoproterenol (beta) (0, 10, 30, 100 nmol/500 nl), and blood samples were taken from the tail tip. In the second experiment a different set of rats received 30 nmol clonidine or vehicle subcutaneously instead of brain microinjections. Intracranial clonidine and isoproterenol produced marked and moderate hyperglycemia, respectively; methoxamine did not alter glucose. For neither clonidine nor isoproterenol was there any difference in hyperglycemia as a function of microinjection site; also, subcutaneous clonidine injections produced the same peak glucose response as was found after both paraventricular and caudate nucleus microinjections of the same dose. Free fatty acid levels were increased by clonidine and isoproterenol, but slightly suppressed by methoxamine; the alpha agonist effects, but not the beta agonist effect, were greater after paraventricular microinjections than after caudate microinjections. Corticosterone was increased by both alpha agonists after paraventricular but not after caudate nucleus microinjections; beta agonist microinjections into the paraventricular and caudate nuclei produced equivalent corticosterone elevations. These results suggest that most, if not all, of the hyperglycemic effects of alpha and beta adrenergic agonist microinjection into the paraventricular nucleus can be ascribed to leakage of the material into the vasculature, with subsequent action at a distant site. In contrast, all 3 agonists seem capable of acting within the brain to alter free fatty acid levels. The effects on corticosterone of both the alpha 1 and alpha 2 agonists, but not the beta agonist, also appear due, at least in part, to actions within the brain. Previous suggestions that catecholamine terminals in the hypothalamic paraventricular nucleus are directly and strongly involved in metabolic fuel regulation may require reconsideration.

Characterization of immunoreactive pancreastatin in porcine tissues

Pancreastatin is a 49 amino acid peptide with a C-terminal glycine amide originally isolated from porcine pancreas. There are strong indications that pancreastatin is derived from chromogranin A, since the amino acid sequence 240-288 in porcine chromogranin A contains pancreastatin flanked by typical signals for proteolytic processing. In the present study the distribution and molecular nature of immunoreactive pancreastatin were examined in selected porcine tissues. For this purpose a radioimmunoassay specific for the C-terminal sequence of porcine pancreastatin, that did not cross-react with porcine chromogranin A was used in combination with gel permeation chromatography and reverse-phase high-pressure liquid chromatography (HPLC). We demonstrated the presence of pancreastatin, a C-terminal pancreastatin fragment and N-terminally extended molecular forms in the examined tissues. Pancreastatin predominated in the pancreas and stomach antrum, while N-terminally extended molecular forms were mainly present in the stomach body, jejunum and adrenal gland. The specific distribution pattern of the molecular forms probably reflects a tissue-specific processing of chromogranin A.

Immunocytochemical localisation of pancreastatin and chromogranin A in porcine neuroendocrine tissues

Pancreastatin is a 49 amino acid peptide with a C-terminal glycine amide originally isolated from porcine pancreas. In the present study the cellular localisation of pancreastatin in porcine neuroendocrine tissue was examined immunocytochemically using an antiserum raised against porcine pancreastatin (33-49) that does not cross-react with porcine chromogranin A. In order to study the possible precursor-product relationship between chromogranin A and pancreastatin the cellular localisation of both peptides was examined in peripheral tissues using simultaneous double immunostaining. The pancreastatin antiserum immunostained cells and nerve fibers throughout the neuroendocrine system. In most of the examined tissues we found colocalisation of pancreastatin and chromogranin A immunostaining. These results support the precursor-product concept for chromogranin A and pancreastatin. However, in the gastrointestinal tract and the adenohypophysis a minor population of the endocrine cells exhibited immunostaining with only one of the two antibodies. This discrepancy between immunostaining with pancreastatin antiserum and monoclonal chromogranin A antibody could be due to absence of, or extensive, processing of chromogranin A in certain cell populations.

Pancreastatin--a novel regulatory peptide?

Pancreastatin is a 49 amino acid peptide originally isolated from porcine pancreas on the basis of its C-terminal glycinamide as isolation criterion. It is derived by proteolytic processing from chromogranin A, an acidic protein component of secretory granules in endocrine and neuronal cells. The primary structures of human, porcine, bovine and rat pancreastatin have been determined on the protein or cDNA level and show 70% sequence homology. By immunocytochemistry, pancreastatin has been detected in the pituitary, adrenal gland, pancreas, CNS and throughout the gastrointestinal tract. In pancreatic islets, pancreastatin is co-localized with insulin, glucagon and somatostatin. The principle biological activities of this peptide are: inhibition of insulin release and of exocrine pancreatic secretion. These effects which can be assigned to the amidated C-terminal part of the molecule have been demonstrated in several species. Whether or not pancreastatin can be classified as a novel peptide hormone that under physiological conditions plays a role in the regulation of the endocrine and exocrine pancreas, is still a matter of controversy.